Nonalcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease in the world, affecting an estimated 25% of the global adult population.1 Liver-related morbidity and mortality attributed to NAFLD are substantial, and fibrosis seems to be the strongest independent predictor of outcome.2 Fibrosis develops among patients with the nonalcoholic steatohepatitis (NASH) phenotype, making it the biologically relevant focus of drug development.3 Currently, there are no approved therapies to treat NASH, although many drugs are in development.